EVA combines machine learning and automated laboratory testing to optimize therapeutic antibodies.
EVA is LabGenius Therapeutics’ antibody discovery and optimization platform. It connects computational design with automated antibody production and laboratory assays in a repeated experimental cycle.
The platform evaluates antibody function and developability together to identify candidate designs. LabGenius describes a modality-agnostic approach that can work with different antibody formats when suitable high-throughput assays are available.
| Attribute | EVA | Generate Platform | HyperBind | |
|---|---|---|---|---|
| Provider | |  |  | |
| Founded | 2012 | 2018 | 2019 | |
| Sells To | Pharmaceutical | Enterprise | Enterprise | |
| Pricing Model | — | Recurring, Software | Recurring, Software | |
| Ownership | Venture-backed | Equity, Venture-backed | Venture-backed |
Provider
Founded 2012
Sells To Pharmaceutical
Pricing Model —
Ownership Venture-backed
Provider
Founded 2018
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Equity, Venture-backed
Provider
Founded 2019
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed
mBER is Manifold Bio's open-source AI framework for designing antibody binders for in vivo drug discovery.
Cyrus Platform is Cyrus Biotechnology's computational protein design offering combining AI and Rosetta-based design with laboratory mutagenesis screening.
AI-enabled natural-product drug discovery platform organizing plant chemistry into a searchable library with machine-learning translation and automated screening.
Biology-First AI platform predicts disease-matched compounds using multi-omics human data and functional validation.
EvoGen is a generative AI platform that designs novel therapeutic proteins.
mBER is Manifold Bio's open-source AI framework for designing antibody binders for in vivo drug discovery.
Cyrus Platform is Cyrus Biotechnology's computational protein design offering combining AI and Rosetta-based design with laboratory mutagenesis screening.
AI-enabled natural-product drug discovery platform organizing plant chemistry into a searchable library with machine-learning translation and automated screening.
Biology-First AI platform predicts disease-matched compounds using multi-omics human data and functional validation.
